Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Active:	No
Cancer Type:	Stomach/ Gastric Cancer	NCT ID:	NCT04592913
Trial Phases:	Phase III	Protocol IDs:	D910GC00001 (primary) NCI-2021-01109 2019-001555-40
Eligibility:	18 - 200 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT04592913

Summary

This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy
Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and
Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).

Objectives

This study investigates treatment of durvalumab or placebo therapy combined with FLOT
chemotherapy (flurouroacil + leucovorin + oxaliplatin + docetaxel) given before surgery
(neoadjuvant) and durvalumab or placebo therapy combined with FLOT chemotherapy after surgery
(adjuvant), will work and be safe for the treatment of resectable (removable by surgery)
gastric or gastroesophageal cancer, and also to better understand the studied disease and
associated health problems.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.